Baird Starts Vor Biopharma, Inc. (VOR) at Outperform
- S&P 500, Nasdaq eye weekly loss as rate-hike worries hit growth stocks
- Foot Locker Erupts 25% After Earnings, Earns Analyst Upgrades as New CEO is a 'Huge Positive'
- Bed Bath & Beyond (BBBY) Crashes 40% on Ryan Cohen Exit, Analyst Warns the Worst is Yet to Come
- Deere (DE) Drops on Big EPS Miss and 'Light' Guidance, Analyst Reactions Mixed
- Market is Betting on Policy Pivot but BofA Warns - Fed is 'Nowhere Near Done'
Baird analyst Jack Allen initiates coverage on Vor Biopharma, Inc. (NASDAQ: VOR) with a Outperform rating and a price target of $38.00.
Shares of Vor Biopharma, Inc. closed at $11.32 yesterday.
You May Also Be Interested In
- UBS Assumes DaVita (DVA) with a Buy
- UPDATE: Oppenheimer Starts Microvast (MVST) at Outperform
- BofA Securities Starts Relay Therapeutics (RLAY) at Buy
Create E-mail Alert Related CategoriesHot New Coverage, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!